1. Home
  2. SRE vs BDX Comparison

SRE vs BDX Comparison

Compare SRE & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBA Sempra

SRE

DBA Sempra

HOLD

Current Price

$99.60

Market Cap

60.5B

Sector

Utilities

ML Signal

HOLD

Logo Becton Dickinson and Company

BDX

Becton Dickinson and Company

HOLD

Current Price

$153.92

Market Cap

51.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRE
BDX
Founded
1998
1897
Country
United States
United States
Employees
15938
N/A
Industry
Oil/Gas Transmission
Medical/Dental Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.5B
51.5B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
SRE
BDX
Price
$99.60
$153.92
Analyst Decision
Buy
Buy
Analyst Count
13
12
Target Price
$100.17
$188.73
AVG Volume (30 Days)
2.8M
2.0M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
2.64%
2.70%
EPS Growth
N/A
N/A
EPS
N/A
1.34
Revenue
N/A
$21,840,000,000.00
Revenue This Year
$5.79
N/A
Revenue Next Year
N/A
$2.22
P/E Ratio
$28.25
$116.08
Revenue Growth
N/A
8.24
52 Week Low
$68.58
$152.99
52 Week High
$101.04
$213.08

Technical Indicators

Market Signals
Indicator
SRE
BDX
Relative Strength Index (RSI) 66.06 33.65
Support Level $90.57 N/A
Resistance Level N/A $160.19
Average True Range (ATR) 1.83 3.06
MACD 0.27 0.97
Stochastic Oscillator 81.64 9.02

Price Performance

Historical Comparison
SRE
BDX

About SRE DBA Sempra

Sempra Energy serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure partners, of which Sempra will hold a 25% ownership, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.

About BDX Becton Dickinson and Company

Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.

Share on Social Networks: